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Neisseria meningitidis is a Gram-negative pathogen that actively invades its human host and leads to the development of life-
threatening pathologies. One of the leading causes of death in the world, N. meningitidis can be responsible for nearly 1,000 new
infections per 100,000 subjects during an epidemic period. The bacterial species are classified into 12 serogroups, five of which
(A, B, C, W, and Y) cause the majority of meningitides. The three purified protein conjugate vaccines currently available target
serogroups A, C, W, and Y. Serogroup B has long been a challenge but the discovery of the complete genome sequence of an MenB
strain has allowed the development of a specific four-component vaccine (4CMenB). This review describes the pathogenetic role
of N. meningitidis and the recent literature concerning the new meningococcal vaccine.
1. Introduction
Neisseria meningitidis is one of the most frequent causes of
meningitis and septicemia worldwide [1, 2], being not only
responsible for 10–20% of specific meningococcal-related
mortality but also the cause of (particularly pediatric) long-
term morbidity [1] as it leads to permanent neurological
sequelae and disabilities in an additional 20% [3–5]. Further-
more, the pediatric mortality rate among children with sepsis
is over 20% [6, 7].The incidence ofmeningococcalmeningitis
is greatest amongst children, adolescents, and adults aged
up to 29 years, but young children are the most susceptible.
The risk of N. meningitidis infection is particularly high in
some regions of the world but, despite the introduction of
innovations in health care, morbidity and mortality rates
are high in both developed and undeveloped countries, and
prevention is therefore a priority.
The bacteria colonise the nasopharyngeal tract of human
hosts and are spread from subject to subject via air droplets.
Transmission rates vary and are also related to individual
risk factors such as age and/or underlying medical and social
conditions (e.g., primary or secondary immunodeficiencies,
a history of travel, and overcrowded living condition). Twelve
different serogroups are known, but most invasive meningo-
coccal diseases are caused by one of the six capsular groups
A, B, C, W, X, and Y.
A number of excellent conjugate vaccines against
serogroups A, C, W, and Y have been licensed, and the
introduction of conjugate meningococcal C vaccine (MenC)
has led to a rapid and sustained reduction in the incidence
of invasive MenC disease across all age groups in Italy [8, 9].
However, a vaccine against capsular group B (MenB), which
has now become responsible for most cases in Italy and
the rest of the world [7, 9], has long eluded vaccinologists,
particularly because of the problems associated with the
B polysaccharide [10–12]. Unlike the highly immunogenic
polysaccharides of serogroups A, C, W, and Y, the serogroup
B polysaccharidic capsule contains a polysialic acid whose
antigenic structure resembles the cell surface glycoproteins
of human neurological tissue, and this has proved to be a
formidable challenge [13].
The new protein-based vaccine against MenB (4CmenB;
Bexsero, Novartis Vaccines and Diagnostics, Siena, Italy) has
now overcome this barrier by using a cocktail of four main
immunogenic components: two recombinant fusion proteins
(Neisseria heparin-binding antigen [NHBA-GNA1030] and
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factor H binding protein [fHbp-GNA2091]), recombinant
Neisseria adhesion A (NadA), and detergent-treated outer
membrane vesicles (OMVs) derived from theNZ98/254New
Zealand meningococcal outbreak strain in which porin A
(PorA 1.4) is the major immunodominant antigen. These
components were identified using reverse vaccinology [14],
a technique that analyses the whole bacterial genome in
order to predict meningococcal antigens (exposed on the
pathogen’s surface or secreted) that can act as vaccine targets.
NHBA is a surface b-barrel lipoprotein that binds to the
anticoagulant heparin and induces protective immunity in
human hosts [15–17], and fHbp is a surface-exposed protein
that allows binding exclusively to human fH [18], mediates
host serum resistance, and induces bactericidal antibodies
upon host detection [15, 19]. NadA is a surface adhesin and
invasinwhose interactionswith abundantly expressed human
heat shock protein 90 (Hsp90) [20] also induce bactericidal
antibodies [21, 22]. NadA expression can be regulated by the
Nad repressor (NadR) [23]. Finally, porA (one of the two
b-barrel porin proteins produced by N. meningitides) [24]
assists in opsonophagocytic activity and is also involved in
host actin reorganisation during infection, which depends on
its ability to nucleate actin filaments.
This four-component meningococcal serogroup B vac-
cine (4CMenB), the first successful vaccine against the
endemic form of this cause of serious bacterial meningitis
and septicemia, has been in development for almost 20 years
and has recently been approved for the active immunisation
of subjects aged ≥2 months [9, 10] by licensing authorities in
Europe, Canada, and Australia.
A bivalent fHbp recombinant vaccine (also known as
LP2086; Trumenba, Pfizer Inc., Philadelphia, PA, USA) has
been developed since 2006 and has now been approved by
the US Food and Drug Administration for use in 10-to-
25-year olds [25]. This vaccine appeared safe in a phase 3
study in approximately 5,600 healthy individuals 10 to 25
years of age and immunogenic and safe when coadministered
with routine meningococcal A, C, Y, and W and tetanus,
diphtheria, and pertussis (Tdap) vaccines in a phase 2 study in
more than 2,600 healthy individuals 10 to 12 years of age [26].
Studies on this vaccine are ongoing in Europe and approval
from European Medicines Agency is expected in 2017.
The aim of this review is to discuss the immunogenicity,
safety, and tolerability of 4CMenB vaccine in infants and
toddlers, and the efficacy of different vaccination strategies.
2. Immunogenicity of 4CMenB
An important challenge for the licensing of 4CMenB vaccine
was the difficulty in showing its activity against epidemio-
logically relevant strains of N. meningitidis [27, 28]. After its
development and phases I and II trials, some large-scale ran-
domised phase III studies were planned in order to assess its
efficacy and describe adverse reactions, but due to the rarity
of the diseases caused by N. meningitides serotype B (which
have annual rates of 0.5–5 per 100,000 people) laboratory-
based methods were developed with the aim of predicting
the vaccine’s effectiveness and coverage [29]. In Europe,
the vaccine was licensed on the basis of a correlate of pro-
tection calculated using a titre of human serum bactericidal
activity (hSBA) that is present in convalescent patients which
was shown to be protective in US Army recruits. HSBA assay
is a recognised in vitro surrogate for evaluating protective
immunity against N. meningitidis, and an adequate response
is a crucial criterion for licensing vaccines against serogroup
B meningococci. In order to justify the inclusion of each
antigen in the formulation, it is necessary to run four hSBA
assays on each serum sample, each using a N. meningitidis
strain expressing the target antigen independently from
the others in order to evaluate immunogenicity of each
component of the vaccine, for example, a meningococcal
strain that uniquely expressesNadAbut not factor-H-binding
protein or Neisseria heparin-binding antigen. Typically, an
hSBA titre of 4 is initially used to assess immunogenicity.
Subsequent phase III studies of 4CMenB in children used a
more conservative titre of ≥5, which ensures that the level
is >4 with 95% confidence taking into account within-assay
variability.
The safety and immunogenicity of 4CMenB vaccine
has been studied when administered at the same time as
other routine infant vaccines (diphtheria, tetanus, acellular
pertussis, inactivated poliovirus, hepatitis B, Haemophilus
influenzae type b [DTaP-IPV-HepB/Hib], and 7-valent pneu-
mococcal conjugate vaccine [PCV7]), and it has been found
that the antibody responses to the routine vaccines are equiv-
alent to those observed when the routine vaccines are given
alone in the case of all of the antigens except for the pertactin
component of acellular pertussis and pneumococcal serotype
6B [10]. However, this laboratory observation seems to be of
no clinical significance, and published data also suggest that
the incidence of pneumococcal disease due to serotype 6B is
low in the countries in which PCV7 vaccination is used.
Other studies have investigated the persistence of bac-
tericidal antibodies in young children after primary immu-
nisation and the level of immunogenicity after a preschool
booster [29, 30]. The levels of bactericidal antibodies after
primary 4CMenB vaccination at the ages of two, four, six,
and 12 months had waned when measured at 40–44 months,
but an anamnestic response was observed following a booster
dose given at the age of 40–44 months [14]. Similarly,
bactericidal antibody levels in infants who originally received
4CMenB during late infancy (6, 8, and 12 months) had also
waned when measured at the age of 40 months but, once
again, there was an anamnestic response to a booster dose
given at 40 months [30].
3. Safety and Tolerability of 4CMenB
The studies assessing the immunogenicity of 4CMenB also
evaluated its safety and tolerability. The participating infants
were observed for 30 minutes after each vaccine admin-
istration, and their parents were given a diary card on
which to record the occurrence and severity of solicited
local (i.e., injection site tenderness, erythema, induration,
and swelling) and systemic reactions (i.e., changes in eating
habits, sleepiness, vomiting, diarrhea, irritability, unusual
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crying, rash, and increased/decreased body temperature) and
any other adverse events, during the following seven days.
The rates of local and systemic reactions were similar to
those seen following other routine infant and early childhood
vaccinations, but injection site pain was consistently reported
more frequently, especially by older children.
Fever was more frequent in the children who received
4CMenB together with other routine infant vaccines. It
mainly occurred during the first 24 hours after administra-
tion but, as in case of other vaccines, it has been found that the
prophylactic administration of paracetamol before and 4–6
hours after vaccination significantly reduces postvaccination
fever without affecting immunological responses [31, 32].
The pivotal and phase IIb studies found that the most
frequently reported local reaction of tenderness affected 87%
of the 4CMenB injection sites, 80% of the DTaP- IPV-
HepB/Hib sites, and 79% of the PCV7 sites when all three
vaccines were administered together [33]. The frequency of
reported tenderness after DTaP-IPV-HepB/Hib and PCV7
injections when they were administered without 4CmenB
was respectively 59% and 53%, whereas when DTaP-IPV-
HepB/Hib and PCV7 injections were administered with
4CmenB it was respectively 68% and 62%.
The reported rates of local reactions to 4CMenB were
slightly higher than those related to routine vaccines [10], but
the majority were transient, most intense on the day after
vaccination, and resolved within a week.
Although the systemic reactions that occurred when
4CMenB was administered concomitantly with routine vac-
cines cannot be specifically attributed to one or other of
the vaccines, it is possible to assess the overall profile. The
occurrence of 4CmenB-related seizures is rare: the combined
data of infant studies including >20,000 vaccinations in the
primary 4CMenB study arm indicate an overall rate 0.1
febrile seizures/1000 vaccinations on the day of vaccination
or the day after and no events in the control arm. They are
similarly rare in toddlers: 0.4 events/1000 vaccinations (95%
confidence interval (CI): 0.05–1.46) after a total of 11,000
4CMenB vaccinations administered with or without routine
vaccines, as against 0.3 event/1000 visits (95% CI: 0.04–1.05)
in the case of those receiving routine vaccines alone [10,
33].
Six suspected cases of Kawasaki disease reported during
the course of two infant studies (four in the pivotal trial and
two in the phase IIb study) were evaluated by an independent
external expert panel in order to assess whether they were
true Kawasaki cases and whether they were vaccine related
[33]. Analysis of the Kawasaki cases indicates an annual
incidence of 72/100,000 person-years (95% CI: 23–169) after
4CmenB vaccinations, as against 56/100,000 person-years
(95% CI: 1–311) after routine vaccinations alone.
The overall data from different studies indicate that the
frequency of febrile seizures, the incidence of Kawasaki
disease, and the proportion of infants using antipyretics
are similar to those observed during clinical licensure pro-
grammes. However, as the number of exposed infants is still
too small to exclude any relationshipwith rare adverse events,
further postmarketing surveillance is necessary.
4. Coverage and Efficacy of 4CMenB
Thenew 4CMenB vaccinemay not protect against all invasive
meningococcal B strains because the antigens included in the
vaccine are expressed by only some of the strains in circu-
lation. However, it is not known what protection 4CMenB
vaccine provides against invasive meningococcal disease
(IMD) because it depends on the vaccine antigens expressed
by the meningococcal strains in any given geographical area
and their cross-reactivity with the antigens included in the
vaccine. Epidemiological and microbiological data regarding
the circulating meningococcal strains are important in order
to predict the theoretical coverage provided by 4CMenB
vaccine and assess its impact on disease burden.
Further postmarketing surveillance will allow a more
precise estimate of the effectiveness of 4CMenB. However,
although an hSBA can be used to demonstrate whether the
vaccine induces antibodies capable of killing meningococcal
strains, the presence of four antigens means that it is more
complex than in the case of other meningococcal vaccines
(i.e., MenC). Moreover, the genetic diversity of serogroup B
strains means that not all of them have the genes coding for
each of the antigens, and their expression may vary over time
or from place to place.
For these reasons, the Meningococcal Antigen Typ-
ing System (MATS) is used to measure bacterial antigen
expression in order to predict whether bactericidal serum is
capable of killing particular strains [34–36]. This method is
characterised by both phenotypic and genotypic analyses: the
expression of the individual antigens that cross-react with the
corresponding vaccine antigen is quantified using polyclonal
antibodies against NHBA, NadA, and fHbp in an enzyme-
linked immunosorbent assay (ELISA), and DNA sequence
homology to the variable region sequence of the vaccine
strain PorA gene is assessed, in order to estimate coverage
in a specific region [32, 33]. It has not yet been proved that
there is a correlation between the MATS results and real
vaccination coverage, but the predicted protection based on
the expression of at least one matched antigen ranges from
73% to 87% [36]. The MATS has been applied to isolates
of 1,052 MenB strains causing IMD in Europe submitted
to reference laboratories in France, Germany, Italy, Norway,
and the UK between 2007 and 2008 [37], and the analysis
demonstrated estimated efficacy values ranging from 73% in
the UK to 87% in Italy. Furthermore, a study conducted in
Canada between 2006 and 2009 analysed 157 MenB isolates
collected from children and adults with IMD and found that
the potential coverage of 4CMenB vaccine was 75–90%. On
the basis of the MATS ELISA findings, the authors predicted
that 66% of the circulating strains were covered by at least one
vaccine antigen although none were covered by all four [38].
A new meningococcal serotype X has recently been
isolated in Africa, against which no vaccine is currently
available. However, some authors have recently used the
MATS and bactericidal assays of 11 serogroup X isolates
taken from nine African and two French patients and found
that 4CMenB vaccine could have a good coverage against
the strains from Africa but not those from France [39].
In regions where meningococcal strains are appropriately
4 Journal of Immunology Research
monitored, the MATS can evaluate the real effectiveness of
4CmenB vaccine, and the development of changes in the
MenB serogroup over time. It is also a very useful means
of monitoring the emergence of new MenB mutants due to
selective vaccination pressure [39].
5. Vaccination Strategies and
Future Perspectives
Although the development of a meningococcal B serogroup
vaccine was slow and difficult, the new Bexsero 4CMenB
vaccine has recently been licensed in the EU, Australia, and
Canada. The introduction of any new vaccine is never easy,
but it is especially complex in this case.
The success of a vaccination programme is based on
both cost-effectiveness and public acceptance and although
meningococcal B infection is a cause for concern in the
general population, the acceptability of the vaccine by parents
is influenced by worries concerning its potential side effects,
its real effectiveness, and the consequences of its coadminis-
tration with other routine vaccines in terms of the number
of injections and possible immunological interference [40].
For example, its acceptance may be reduced by the fact
that it has been associated with increased rates of fever
when coadministered with the routine vaccinations provided
during infancy on the basis of the national immunisation
schedules.
One recent study of parental attitudes to 4CMenB showed
that 82.5% of the interviewees wanted their children vacci-
nated.Themost frequent concerns were side effects including
fever (41.3%) and adequate vaccine testing (11.7%), but 26%
of the parents said that they had no concerns. Moreover, as
in the case of other vaccinations (e.g., HPV), the authors
found thatmost parents (81.7%)weremore likely to accept the
vaccination if their immunisation providers recommended it
[41].
The vaccination schedule should take into account the age
of the subjects most frequently affected by meningococcal
disease and the epidemiology of meningococcal infections.
One recent study aimed at defining the optimal age for
administering 4CMenB to children has shown that the
incidence is highest in those aged <5 years (particularly those
in their in the first year of life, when deaths aremore frequent)
and, on the basis of this finding, the authors suggested that
vaccination should be started in the first year of life, with a
catch-up dose being given at the age of five years [42].
Other recent studies have evaluated the cost-effectiveness
of a potential MenB vaccination programme [43, 44]. One
study carried out inTheNetherlands estimated that an infant
MenB vaccination programme would prevent 14% of cases
over the lifetime of a birth cohort and concluded that this was
not cost-effective [44] and although another study carried out
in the UK estimated that routine vaccination would prevent
27–56%of cases over the lifetime of a birth cohort, the authors
also considered it not cost-effective [41]. Finally, a recent
study of the economic impact ofMenB vaccination inCanada
found that the MenB vaccination programme exceeds
the generally cost-effectiveness thresholds and therefore
should not be considered economically advantageous [45].
Nevertheless, 4CMenB is now being used in Canada
and, upon parents’ request, also in all of the countries and
it has been licensed and its use in at-risk populations has
been implemented. It has also been announced that it may
be introduced into the UK’s routine infant immunisation
schedule using a 2 + 1 regimen although only a 3 + 1 regimen
with the concomitant use of paracetamol is currently licensed
[46], and some other countries are reconsidering their cost-
effectiveness calculations by also considering its possible
impact on carrier status [47].
With the availability of the bivalent rLP2086 vaccine
for the adolescent age, it will be important to compare
vaccination strategies that cover different age groups as well
as to understand the impact of the two vaccines against IMD
overall, meningococcal disease due to serogroups different
fromMenB andmeningococcal carriage in the nasopharynx.
6. Conclusions
N. meningitidis is still one of the major causes of sepsis and
meningitis among children worldwide and is associated with
a high mortality rate. Considerable efforts have therefore
been made to prevent meningococcal disease by means
of vaccination, and two effective conjugate vaccines have
recently been licensed and led to good results (Men C
and MenACYW). However, it proved to be very difficult
to develop a vaccine against serogroup B because of the
poor immunogenicity of its capsular polysaccharide, even
when conjugated with a carrier that could also induce an
autoimmune response, until experts used reverse vaccinology
to identify appropriate antigenic recombinant proteins. The
overall findings of various studies have shown that the admin-
istration of three doses of 4CmenB to young children (alone
or with routine vaccines) does not interfere with immune
responses, andmost have found that its safety and tolerability
are acceptable. However, its coadministration with other
vaccines does lead to increased reactogenicity (particularly
fever) and so such coadministration should be combinedwith
paracetamol given both before and after vaccination.
The new 4CMenB vaccine represents an important
opportunity to fight pediatric IMDs, but its introduction
should take into account the need to maintain the appro-
priate use of meningococcal conjugate vaccines that cover
serogroups other than B, community opinion, and cost-
effectiveness data. Moreover, it will be important to compare
4CMenB potential efficacy with that of bivalent rLP2086
vaccine. Finally, it is very important to continue surveillance
in order to monitor the emergence of new meningococcal
B strains in order to identify any that are not susceptible to
4CMenB.
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